NCT01670357View on ClinicalTrials.gov

Phase II Study of DA-6034 Eye Drops in Dry Eye Syndrome

PHASE2CompletedINTERVENTIONAL
Enrollment

150

Participants

Timeline

Start Date

April 30, 2012

Primary Completion Date

March 31, 2013

Study Completion Date

March 31, 2013

Conditions
Dry Eye Syndrome
Interventions
DRUG

DA-6034 3%

Eye drop, 1 drop/each eye, 4 times/day, for 4 weeks

DRUG

DA-6034 5%

Eye drop, 1 drop/each eye, 4 times/day, for 4 weeks

DRUG

DA-6034 Placebo

Eye drop, 1 drop/each eye, 4 times/day, for 4 weeks

Trial Locations (1)

137-701

Seoul St.Mary's hospital, Seoul

All Listed Sponsors
lead

Dong-A ST Co., Ltd.

INDUSTRY

NCT01670357 - Phase II Study of DA-6034 Eye Drops in Dry Eye Syndrome | Biotech Hunter | Biotech Hunter